Kmpharmaceutical케이엠제약
225430 · KOSDAQ · ₩225430 · 케이엠제약
₩698 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩16B | ₩14B | ₩18B | ₩16B | ₩23B |
| Cost of sales | ₩12B | ₩11B | ₩13B | ₩12B | ₩17B |
| Gross profit | ₩3.8B | ₩3.6B | ₩4.9B | ₩3.2B | ₩5.7B |
| Operating income | −₩2.9B | −₩2.6B | −₩1.1B | −₩1.2B | ₩866M |
| Net income | −₩4B | −₩4.6B | −₩1.3B | −₩3.9B | −₩611M |
| Net income to shareholders | −₩4B | −₩4.6B | −₩1.3B | −₩3.9B | −₩611M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩46B | ₩49B | ₩51B | ₩51B | ₩53B |
| Current assets | ₩3.8B | ₩4.7B | ₩6B | ₩6.3B | ₩9.8B |
| Cash and equivalents | ₩351M | ₩221M | ₩953M | ₩448M | ₩2.1B |
| Total liabilities | ₩18B | ₩16B | ₩15B | ₩15B | ₩13B |
| Current liabilities | ₩12B | ₩9.3B | ₩12B | ₩12B | ₩7.5B |
| Borrowings | ₩11B | ₩14B | ₩12B | ₩13B | ₩9.5B |
| Total equity | ₩28B | ₩33B | ₩35B | ₩36B | ₩40B |
| Shareholders' equity | ₩28B | ₩33B | ₩35B | ₩36B | ₩40B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Capital spending | ₩258M | ₩365M | ₩113M | ₩10M | ₩2.4B |
Consolidated where available. Amounts in won.
Also known as: Kmpharmaceutical / 케이엠제약 / 225430 / KRX:225430
Source: KRX statistical information